The content on this site is intended for healthcare professionals only
According to research presented by Professor Mathieu Boniol, at the 2013 European Cancer Congress (ECC 2013) men experience more harm than good from routine PSA screening.
Prostate cancer screening using the prostate-specific antigen (PSA) test is widely used in France despite a lack of evidence showing that it reduces cancer deaths.
Prof Boniol, Research Director at the International Prevention Research Institute (iPRI) and Professor at the Strathclyde Institute for Global Public Health at iPRI, Lyon, France, will tell the congress that the total harm men experience in terms of impotence and incontinence, and the side-effects from prostate cancer treatments, severely affects their quality of life, and should further discourage the use of PSA testing for prostate cancer screening.
Read more on ecancerNews
ecancer's filming at ECC has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing
Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities
Powering equity in cancer care through digital health
Choosing Wisely for young women with breast cancer: Radiotherapy
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Best practice in HRRm testing in patients with metastatic prostate cancer
Genomic testing: Awareness and effective communication between healthcare professionals and patients
The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer
